CIR.L Share News (CIR)

LONDON MARKET OPEN: Stocks Down But Whitbread Gains As Sales Grow

LONDON MARKET CLOSE: Remain-led Polls Drive "Frenzy Of Buying"

London midday: Financials pace gains as Footsie keeps climbing

(ShareCast News) - Stocks in London were continuing to move higher come midday on Monday, alongside the largest gain the pound in three months, with investors taking their cue from strong gains in Asia as Brexit polls showed the Remain campaign was in the lead. As of 12:03 BST, the FTSE 100 was 183.

LONDON MARKET MIDDAY: Receding Brexit Fear Lifts Stocks And Pound

WINNERS & LOSERS SUMMARY: Cat Allergy Disappointment Sinks Circassia

London open: Stocks surge after latest poll results

(ShareCast News) - Stocks in London surged at the start of trading, alongside the largest gain the pound in three months, with investors taking their cue from strong gains in Asia as Brexit polls showed the Remain campaign was in the lead. As of 08:43 BST the FTSE 100 was 145.82 points or 2.42% high

LONDON MARKET OPEN: Stocks Gain As Polls Swing In Favour Of Remain

Circassia plummets after cat allergy drug fails placebo test

(ShareCast News) - Shares in biopharmaceutical development company Circassia Pharmaceuticals plummeted on Monday morning, after it announced disappointing top-line results from its investigational cat allergy immunotherapy phase III study. At 0815 BST, shares in Circassia were down 55.86% at 119.3p.

Circassia Pharmaceuticals: "Dramatic" Placebo Effect In Allergy Study

Circassia to report Phase 3 trial results for cat allergy treatment in coming weeks

(ShareCast News) - Circassia Pharmaceuticals kicked off phase-three trials for its grass allergy treatment, the second imunotherapy programme for which it was seeking regulatory approval, and said it was on-track to report the results of its phase-three clinical trials for its Cat allergy treatment

Circassia Begins Final Clinical Testing Phase For Grass Allergy Drug

AGM, EGM Calendar - Week Ahead

Imperial Innovations Portfolio Value Rises, First Half Loss Narrows

BROKER RATINGS SUMMARY: HSBC And Merrill Lynch Downgrade Admiral

Circassia Pharmacuticals reports first revenue

(ShareCast News) - Circassia Pharmaceuticals became a revenue-making business in 2015, and was making firm progress on a number of its products under development, it reported in its preliminary results on Friday. The FTSE 250 company published robust revenue growth through the calendar year through